Piper Jaffray Reiterates an 'Overweight' Rating on Genzyme (GENZ); Making the Right Moves
Tweet Send to a Friend
Piper Jaffray reiterates an 'Overweight' rating on Genzyme (Nasdaq: GENZ), raises price target from $66 to $70.
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
